Evidence map›Paper›PMID 40625868›Full record

ArticleHealth affairs scholar2025

Local population characteristics and access equity of 340B contract pharmacies.

Maura Coughlin, Dibya Deepta Mishra

Abstract read
In one paragraph

Article in Health affairs scholar, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Maura CoughlinDepartment of Economics, Rice University, Houston, TX 77005, United States.ORCID https://orcid.org/0000-0002-5228-1188

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 340B Drug Pricing Program allows certain US medical entities with vulnerable patient populations to receive large discounts on outpatient prescriptions and use those savings at the entity's discretion. Since reforms in 2010, the number of pharmacies with whom 340B entities contract grew massively. This article explores the locations of 340B contract pharmacies and corresponding local populations within Texas. We measured and tested for statistical differences in population characteristics between 340B and non-340B pharmacies and the association with other local amenities. We focused on measures of pharmacy accessibility, local population social vulnerability, and local access to other crucial amenities, measures of population well-being previously not investigated in this debate. We found that 340B and non-340B pharmacies are located in fairly similar local populations, but 340B pharmacies are located in statistically significantly less-vulnerable populations than the facilities with which they contract. We found that comparisons of pharmacy accessibility measures are complicated by sensitivity to data sources. Our results suggest that the contract pharmacy program within Texas may target less-vulnerable populations through the shift from covered entity pharmacies to outside pharmacies. Impacts on the target patient population at the covered entity require further research to measure.

Indexed as

340B drug pricingpharmacies

Identifiers

PMID40625868
PMCPMC12230945

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.